LUCD · Lucid Diagnostics Inc.

Lucid Diagnostics Inc. closed an underwritten public offering of 18,000,000 shares of common stock at $1.00 per share, generating gross proceeds of approximately $18 million. The offering was anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder. Net proceeds, after deducting underwriting discounts and estimated expenses, are expected to be approximately $16.8 million. The company intends to use the net proceeds for working capital and general corporate purposes. Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners. The offering was made pursuant to an effective shelf registration statement on Form S-3. This capital raise strengthens Lucid's balance sheet as it continues to commercialize its EsoGuard esophageal DNA test and EsoCheck cell collection device for early detection of esophageal precancer.